ALKERMES, INC.
A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)
- First Posted Date
- 2016-02-29
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 561
- Registration Number
- NCT02694328
- Locations
- 🇵🇷
Alkermes Investigational Site, San Juan, Puerto Rico
A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
- First Posted Date
- 2016-02-01
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 281
- Registration Number
- NCT02669758
- Locations
- 🇺🇦
Alkermes Investigational Site, Vinnytsia, Ukraine
A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
- Conditions
- Interventions
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT02636842
- Locations
- 🇺🇸
Alkermes Investigative Site, Dallas, Texas, United States
🇺🇸Alkermes Investigational Site, Marlton, New Jersey, United States
A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT02634320
- Locations
- 🇺🇸
Alkermes Investigational Site, DeSoto, Texas, United States
A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2018-06-27
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 403
- Registration Number
- NCT02634346
- Locations
- 🇺🇦
Alkermes Investigational Site, Vinnytsia, Ukraine
A Drug-drug Interaction Study of ALKS 5461 in Healthy Volunteers
- First Posted Date
- 2015-09-10
- Last Posted Date
- 2015-11-10
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02545439
- Locations
- 🇺🇸
Alkermes Investigational Site, Overland Park, Kansas, United States
Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)
- Conditions
- Interventions
- First Posted Date
- 2015-09-01
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 380
- Registration Number
- NCT02537574
- Locations
- 🇺🇸
TRY Research, Maitland, Florida, United States
🇺🇸CNS Healthcare, Orlando, Florida, United States
🇺🇸University Of Pennsylvania - Treatment Research Center, Philadelphia, Pennsylvania, United States
A Water Consumption Study of ALKS 5461 in Healthy Volunteers
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2015-11-10
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02521857
- Locations
- 🇺🇸
Alkermes Investigational Site, Overland Park, Kansas, United States
Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function
- First Posted Date
- 2015-07-27
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT02508506
- Locations
- 🇺🇸
Alkermes Investigational SIte, Orlando, Florida, United States
🇺🇸Alkermes Investigational Site, Minneapolis, Minnesota, United States
A Study of [14c]-Samidorphan (Also Known as ALKS 33) in Healthy, Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2015-07-22
- Last Posted Date
- 2015-09-18
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02504463
- Locations
- 🇺🇸
Alkermes Investigational Site, Austin, Texas, United States